A small, biotechnology company was planning a 5 year, phase III, randomised, double-blinded, placebo-controlled study. The study was conducted across multiple sites in the United States involving 10,600 patients.
This company utilised the expertise of Almac’s Supply Chain Management team to supplement their limited internal resources. Their oversight ensured continuity of drug supply when patient recruitment was x 3 times faster than anticipated.
Download the case study to learn more.